EP300 promotes hepatocellular carcinoma proliferation, migration and in vivo tumorigenicity revealed by integrated experimental and bioinformatic analyses
J Transl Med
.
2026 Feb 4.
doi: 10.1186/s12967-026-07768-0.
Online ahead of print.
Authors
Zhipeng Liu
#
1
,
Junbin Wang
#
2
,
Xia Wu
3
,
Hong Shi
3
,
Youming Ding
4
,
Xuejian Liu
5
Affiliations
1
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.
2
The Second Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250355, China.
3
Cancer Center, Shandong Provincial Third Hospital, Shandong University, Jinan, Shandong, 250031, China.
4
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China. dingym62@163.com.
5
Cancer Center, The First Rehabilitation Hospital of Shandong Province, Linyi, Shandong, 276300, China. lxj15562663553@163.com.
#
Contributed equally.
PMID:
41639884
DOI:
10.1186/s12967-026-07768-0
No abstract available
Keywords:
EP300; Epigenetics; Hepatocellular carcinoma; Metabolic reprogramming; Therapeutic target.